Prescribing glucose-lowering drugs for patients with cardiac disease

Br J Cardiol 2018;25:73–6doi:10.5837/bjc.2018.016 Leave a comment
Click any image to enlarge
Authors:

The past decade has seen the emergence of several new classes of drugs for the treatment of type 2 diabetes mellitus (T2DM). Despite the increasing use of these agents, metformin and sulfonylureas remain the most commonly prescribed glucose-lowering drugs in people with T2DM. This reflects the National Institute for Health and Care Excellence (NICE) guideline from 2015 and the Scottish Intercollegiate Guidelines Network (SIGN) guideline from 2010, which recommended metformin as first-line treatment and sulfonylureas as the ‘usual’ second-line treatment for patients with T2DM. SIGN has recently provided an updated guideline on the pharmacological management of glycaemic control in people with T2DM. For the first time in UK guidelines, this recommends that in individuals with diabetes and cardiovascular disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists with proven cardiovascular benefit (currently empagliflozin, canagliflozin and liraglutide) should be considered. It is anticipated that implementation of these new guidelines will lead to increased prescribing of these drugs in people with diabetes and cardiac disease, with reductions in prescribing of dipeptidyl peptidase-4 (DPP-4) inhibitors and other drugs in the GLP-1 receptor agonist class, where cardiovascular benefits have not been clearly demonstrated.

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.


You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT